EXICURE, INC.
XCUR · XNASCIK 1698530fmd_1KSEA26R30E3CB0NA7FMGZTM97Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2026, 42 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 10 | 0 | 1 | 17 | (0) | 29 | 0 | 1 | 0 |
| Research and development | 14 | 13 | 14 | 19 | 32 | 49 | 20 | 1 | 0 | 3 |
| Total operating expenses | 17 | 20 | 22 | 28 | 42 | 62 | 31 | 15 | 13 | 4 |
| Operating income | (16) | (10) | (22) | (27) | (25) | (63) | (2) | (15) | (12) | (4) |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (1) | (1) | (1) | 0 | 1 | (2) | (1) | (2) | 3 | (1) |
| Income before taxes | (17) | (12) | – | (26) | (25) | (64) | (2) | (17) | (10) | (6) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) |
| Net income from continuing operations | (17) | (12) | – | (26) | (25) | (64) | (3) | (17) | (10) | (5) |
| Net income | (17) | (11) | (22) | (26) | (25) | (64) | (3) | (17) | (10) | (5) |
| Net income to common shareholders | – | – | – | – | (25) | (64) | (3) | (17) | (10) | (5) |